Suscribirse

The effect of antifibrinolytic agents in periacetabular osteotomy: A systematic review and meta-analysis - 12/06/22

Doi : 10.1016/j.otsr.2022.103271 
Chul-Ho Kim a, Eic Ju Lim b, Siyeon Kim c, Ji Wan Kim d,
a Department of Orthopedic Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 
b Department of Orthopedic Surgery, College of Medicine, Chungbuk National University, Cheongju, Republic of Korea 
c Department of Orthopedic Surgery, Gachon University Gil Medical Center, 21, Namdong-daero 774 beon-gil, Namdong-gu, Incheon, Republic of Korea 
d Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro, 43-gil, Songpa-gu, Seoul, Republic of Korea 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Periacetabular osteotomy (PAO) is a major hip preservation surgery for developmental dysplasia of the hip. It is inevitably associated with significant blood loss, so it requires frequent transfusions and could be a cause of perioperative morbidity. However, to date, a large number of studies has not evaluated the effect of antifibrinolytic agents in PAO. Therefore we performed a systematic review and meta-analysis to assess if antifibrinolytics would be effective in reducing blood loss and transfusion rate after PAO surgery.

Methods

In this systematic review and meta-analysis, MEDLINE, Embase, and Cochrane Library databases were systematically searched for studies published before April 4, 2020, that investigated the effect of antifibrinolytic agents in PAO. A pooled analysis was designed to identify differences between antifibrinolytic and control groups focusing on blood loss, transfusion, operation time, postoperative venous thromboembolism (VTE), and length of hospital stay.

Results

We included five studies involving 507 patients (antifibrinolytic group: 256; control group: 251). The pooled analysis showed that the control group had a greater total estimated blood loss (EBL) than the antifibrinolytic group (mean difference [MD]=−257.60mL, 95% confidence interval [CI] −389.68 to −125.53, p=0.0001), but there were no statistical differences in intraoperative EBL (MD=−46.46mL, 95% CI: −192.57 to 99.64, p=0.53). The allogenic transfusion rate was higher in the control group than in the antifibrinolytic group (odds ratio [OR] 0.21, 95% CI: 0.10–0.43, p<0.0001), but there was no difference in the autogenic transfusion rate (OR 0.35, 95% CI: 0.09–1.43, p=0.14). The pooled result showed no difference in operation time (MD=9.13min, 95% CI: −8.54 to 26.80, p=0.31). For the VTE rate, a pooled analysis was not conducted due to the lack of data. The length of hospital stay showed no differences (MD=−0.51 days, 95% CI: −1.17 to 0.16, p=0.13).

Conclusions

Antifibrinolytic use in PAO has positive effects in terms of reduced total EBL and allogenic transfusion rate.

Level of evidence

III; meta-analysis.

El texto completo de este artículo está disponible en PDF.

Keywords : Antifibrinolytics, Antifibrinolytic agent, Tranexamic acid, Epsilon-aminocaproic acid, Periacetabular osteotomy, Meta-analysis


Esquema


© 2022  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 108 - N° 4

Artículo 103271- juin 2022 Regresar al número
Artículo precedente Artículo precedente
  • Hip survivorship following the Bernese periacetabular osteotomy for the treatment of acetabular dysplasia: A systematic review and meta-analysis
  • Joelle Hwee Inn Tan, Si Heng Sharon Tan, Meetrra Seyher Rajoo, Andrew Kean Seng Lim, James Hoipo Hui
| Artículo siguiente Artículo siguiente
  • Do the outcomes of hip arthroscopy for femoroacetabular impingement change over time?
  • Patrick G. Robinson, Helen Lu, Tom Williamson, Julian F. Maempel, Iain Murray, Deborah J. MacDonald, David F. Hamilton, Paul Gaston

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.